Strategies to combat coccidioidomycosis: Are we making any progress?

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Coccidioidomycosis is caused by the dimorphic fungi Coccidioides immitis and Coccidioides posadasii. One of the endemic mycoses, this organism has been found solely in the semiarid to arid life zones of the southwestern United States, Mexico, and parts of Central America and South America. Clinical manifestations of disease vary greatly between patients and are largely dependent upon both the extent of exposure and the immune status of the host. The incidence of coccidioidomycosis continues to rise within the United States. Primary coccidioidal pneumonia accounts for close to 25% of all community-acquired pneumonia within endemic regions, reflecting the substantial burden of disease and health care costs associated with this infection. Although most patients with coccidioidomycosis resolve their initial infection without long-term complications, a minority of patients develop complications of disease ranging from asymptomatic pulmonary nodules to life-threatening disease such as meningitis. This review focuses on the epidemiology, clinical manifestations, spectrum of disease, and treatment options currently available for coccidioidomycosis.

Original languageEnglish (US)
Pages (from-to)215-223
Number of pages9
JournalCurrent Fungal Infection Reports
Volume5
Issue number4
DOIs
StatePublished - 2011

Fingerprint

Coccidioidomycosis
Coccidioides
Pneumonia
Southwestern United States
Asymptomatic Diseases
Central America
Mycoses
South America
Mexico
Infection
Meningitis
Health Care Costs
Epidemiology
Fungi
Lung
Incidence

Keywords

  • Antifungal agents
  • Coccidioidal pneumonia
  • Coccidioides
  • Coccidioidomycosis
  • Diagnosis
  • Epidemiology
  • Immunogenetics
  • Prophylaxis
  • Pulmonary complications
  • Risk factors
  • Treatment
  • Vaccine

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Strategies to combat coccidioidomycosis : Are we making any progress? / Thompson, George Richard.

In: Current Fungal Infection Reports, Vol. 5, No. 4, 2011, p. 215-223.

Research output: Contribution to journalArticle

@article{03d5a104c3f34e4793f2c594d5006469,
title = "Strategies to combat coccidioidomycosis: Are we making any progress?",
abstract = "Coccidioidomycosis is caused by the dimorphic fungi Coccidioides immitis and Coccidioides posadasii. One of the endemic mycoses, this organism has been found solely in the semiarid to arid life zones of the southwestern United States, Mexico, and parts of Central America and South America. Clinical manifestations of disease vary greatly between patients and are largely dependent upon both the extent of exposure and the immune status of the host. The incidence of coccidioidomycosis continues to rise within the United States. Primary coccidioidal pneumonia accounts for close to 25{\%} of all community-acquired pneumonia within endemic regions, reflecting the substantial burden of disease and health care costs associated with this infection. Although most patients with coccidioidomycosis resolve their initial infection without long-term complications, a minority of patients develop complications of disease ranging from asymptomatic pulmonary nodules to life-threatening disease such as meningitis. This review focuses on the epidemiology, clinical manifestations, spectrum of disease, and treatment options currently available for coccidioidomycosis.",
keywords = "Antifungal agents, Coccidioidal pneumonia, Coccidioides, Coccidioidomycosis, Diagnosis, Epidemiology, Immunogenetics, Prophylaxis, Pulmonary complications, Risk factors, Treatment, Vaccine",
author = "Thompson, {George Richard}",
year = "2011",
doi = "10.1007/s12281-011-0066-6",
language = "English (US)",
volume = "5",
pages = "215--223",
journal = "Current Fungal Infection Reports",
issn = "1936-3761",
publisher = "Current Science, Inc.",
number = "4",

}

TY - JOUR

T1 - Strategies to combat coccidioidomycosis

T2 - Are we making any progress?

AU - Thompson, George Richard

PY - 2011

Y1 - 2011

N2 - Coccidioidomycosis is caused by the dimorphic fungi Coccidioides immitis and Coccidioides posadasii. One of the endemic mycoses, this organism has been found solely in the semiarid to arid life zones of the southwestern United States, Mexico, and parts of Central America and South America. Clinical manifestations of disease vary greatly between patients and are largely dependent upon both the extent of exposure and the immune status of the host. The incidence of coccidioidomycosis continues to rise within the United States. Primary coccidioidal pneumonia accounts for close to 25% of all community-acquired pneumonia within endemic regions, reflecting the substantial burden of disease and health care costs associated with this infection. Although most patients with coccidioidomycosis resolve their initial infection without long-term complications, a minority of patients develop complications of disease ranging from asymptomatic pulmonary nodules to life-threatening disease such as meningitis. This review focuses on the epidemiology, clinical manifestations, spectrum of disease, and treatment options currently available for coccidioidomycosis.

AB - Coccidioidomycosis is caused by the dimorphic fungi Coccidioides immitis and Coccidioides posadasii. One of the endemic mycoses, this organism has been found solely in the semiarid to arid life zones of the southwestern United States, Mexico, and parts of Central America and South America. Clinical manifestations of disease vary greatly between patients and are largely dependent upon both the extent of exposure and the immune status of the host. The incidence of coccidioidomycosis continues to rise within the United States. Primary coccidioidal pneumonia accounts for close to 25% of all community-acquired pneumonia within endemic regions, reflecting the substantial burden of disease and health care costs associated with this infection. Although most patients with coccidioidomycosis resolve their initial infection without long-term complications, a minority of patients develop complications of disease ranging from asymptomatic pulmonary nodules to life-threatening disease such as meningitis. This review focuses on the epidemiology, clinical manifestations, spectrum of disease, and treatment options currently available for coccidioidomycosis.

KW - Antifungal agents

KW - Coccidioidal pneumonia

KW - Coccidioides

KW - Coccidioidomycosis

KW - Diagnosis

KW - Epidemiology

KW - Immunogenetics

KW - Prophylaxis

KW - Pulmonary complications

KW - Risk factors

KW - Treatment

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84905088931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905088931&partnerID=8YFLogxK

U2 - 10.1007/s12281-011-0066-6

DO - 10.1007/s12281-011-0066-6

M3 - Article

AN - SCOPUS:84905088931

VL - 5

SP - 215

EP - 223

JO - Current Fungal Infection Reports

JF - Current Fungal Infection Reports

SN - 1936-3761

IS - 4

ER -